Larimar Therapeutics (LRMR) Projected to Post Quarterly Earnings on Monday

Larimar Therapeutics (NASDAQ:LRMR) is projected to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Larimar Therapeutics to post earnings of ($0.41) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 12:30 PM ET.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.30). On average, analysts expect Larimar Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Larimar Therapeutics Stock Down 4.7%

Shares of NASDAQ LRMR opened at $4.62 on Friday. The firm has a market cap of $479.93 million, a PE ratio of -2.09 and a beta of 0.91. Larimar Therapeutics has a 12-month low of $1.61 and a 12-month high of $6.42. The company’s fifty day simple moving average is $4.09 and its 200 day simple moving average is $3.95.

Insider Buying and Selling at Larimar Therapeutics

In other Larimar Therapeutics news, Director James E. Flynn acquired 5,000,000 shares of Larimar Therapeutics stock in a transaction dated Friday, February 27th. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $25,000,000.00. Following the completion of the acquisition, the director directly owned 10,622,957 shares of the company’s stock, valued at $53,114,785. This represents a 88.92% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 4.50% of the company’s stock.

Institutional Investors Weigh In On Larimar Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its stake in Larimar Therapeutics by 75.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock valued at $33,000 after purchasing an additional 4,376 shares during the last quarter. Coldstream Capital Management Inc. purchased a new stake in shares of Larimar Therapeutics in the third quarter worth approximately $57,000. Commonwealth Equity Services LLC purchased a new stake in shares of Larimar Therapeutics in the fourth quarter worth approximately $87,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Larimar Therapeutics by 26.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,008 shares of the company’s stock valued at $111,000 after purchasing an additional 6,038 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Larimar Therapeutics in the fourth quarter valued at approximately $116,000. Institutional investors and hedge funds own 91.92% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Leerink Partners upgraded shares of Larimar Therapeutics to a “strong-buy” rating in a report on Monday, January 5th. Truist Financial upgraded Larimar Therapeutics to a “strong-buy” rating in a research note on Wednesday. Wedbush boosted their target price on Larimar Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, March 20th. Lifesci Capital raised Larimar Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 24th. Finally, Citigroup increased their price target on Larimar Therapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $16.50.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.